Summary Background The WHO End TB Strategy requires drug susceptibility testing and
treatment of all people with tuberculosis, but second-line diagnostic testing with line-probe …

Despite numerous intervention strategies, including the direct observed short-course
treatment strategy and improved diagnostic methods, the incidence of multidrug-resistant …

Molecular technology revolutionized the diagnosis of tuberculosis (TB) with a paradigm shift
to faster, more sensitive, clinically relevant patient care. The most recent molecular leader is …

Background Drug-resistant tuberculosis (DR-TB) remains a threat to global public health,
owing to the complexity and delay of diagnosis and treatment. The Global Consortium for …

Early detection of resistance to second-line antituberculosis drugs is important for the
management of multidrug-resistant tuberculosis (MDR-TB). The GenoType MTBDR sl …

Background Genotype® MTBDRsl (MTBDRsl) is a rapid DNA‐based test for detecting
specific mutations associated with resistance to fluoroquinolones and second‐line injectable …

Background Genotypic (molecular) methods have considerable advantages for scaling up
programmatic management and surveillance of drug-resistant tuberculosis (TB), offering …

Background The incidence of multidrug-resistant tuberculosis (MDR-TB) is increasing and
the emergence of extensively drug-resistant tuberculosis (XDR-TB) is a major challenge …

Background Several reviews on the accuracy of Tuberculosis (TB) Nucleic Acid
Amplification Tests (NAATs) have been performed but the evidence on their impact on …

Background The Xpert MTB/RIF test enables rapid detection of tuberculosis (TB) and
rifampicin resistance. The World Health Organization recommends Xpert for initial diagnosis …